- Home
- NETD vs KMDA Comparison
NETD vs KMDA Comparison
Compare NETD & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NETD
- KMDA
- Stock Information
- Founded
- NETD 2023
- KMDA 1990
- Country
- NETD United States
- KMDA Israel
- Employees
- NETD N/A
- KMDA N/A
- Industry
- NETD
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- NETD
- KMDA Health Care
- Exchange
- NETD Nasdaq
- KMDA Nasdaq
- Market Cap
- NETD 417.9M
- KMDA 380.7M
- IPO Year
- NETD 2023
- KMDA N/A
- Fundamental
- Price
- NETD $11.03
- KMDA $6.89
- Analyst Decision
- NETD
- KMDA Strong Buy
- Analyst Count
- NETD 0
- KMDA 3
- Target Price
- NETD N/A
- KMDA $14.67
- AVG Volume (30 Days)
- NETD 199.6K
- KMDA 53.8K
- Earning Date
- NETD 01-01-0001
- KMDA 05-14-2025
- Dividend Yield
- NETD N/A
- KMDA 2.89%
- EPS Growth
- NETD N/A
- KMDA 66.67
- EPS
- NETD 0.45
- KMDA 0.25
- Revenue
- NETD N/A
- KMDA $160,953,000.00
- Revenue This Year
- NETD N/A
- KMDA $14.01
- Revenue Next Year
- NETD N/A
- KMDA $9.24
- P/E Ratio
- NETD $24.45
- KMDA $27.37
- Revenue Growth
- NETD N/A
- KMDA 12.93
- 52 Week Low
- NETD $10.50
- KMDA $4.74
- 52 Week High
- NETD $11.10
- KMDA $9.15
- Technical
- Relative Strength Index (RSI)
- NETD 63.81
- KMDA 58.32
- Support Level
- NETD $10.97
- KMDA $6.69
- Resistance Level
- NETD $11.03
- KMDA $7.10
- Average True Range (ATR)
- NETD 0.03
- KMDA 0.16
- MACD
- NETD 0.00
- KMDA 0.05
- Stochastic Oscillator
- NETD 50.00
- KMDA 72.00
About NETD Nabors Energy Transition Corp. II
Nabors Energy Transition Corp II is a blank check company.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.